Panitumumab is a fully human IgG2 monoclonal antibody specific to the epidermal growth factor receptor (EGFR). Panitumumab works by binding to the extracellular domain of the EGFR preventing its activation. This results in halting of the cascade of intracellular signals dependent on this receptor. The pharmacokinetics (PK) of panitumumab shows the so-called target-mediated disposition behavior.
ACS Appl Mater Interfaces. 2023 Jan 26.
Protein Release by Controlled Desorption from Transiently Cationic Nanoparticles
Panitumumab purchased from AbMole
|Storage||-80°C for long term|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related EGFR/HER2 Products|
Unecritinib is a potent EGFR tyrosine kinase inhibitor that inhibits ALK, ROS1, and MET and has anticancer activity. Unecritinib is indicated for use in studies of solid tumors and ALK-positive anaplastic large cell lymphoma.
Almonertinib mesylate is an orally active, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR sensitization and T790M resistance mutations, and also shows strong inhibitory activity against T790M, T790M/L858R, and T790M/Del19, with IC50 of 0.37, 0.29, and 0.21 nM, respectively. The IC50 of T790M/Del19 was 0.37, 0.29 and 0.21 nM, respectively, but the inhibitory effect on wild-type was weaker, with an IC50 of 3.39 nM. It can be used in the research of non-small cell lung cancer.
MAPK-IN-2 is a potent MAPK inhibitor with antineoplastic activity.
EGFR-IN-81 is an EGFR inhibitor.
EGFR-IN-85 is an EGFR inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.